Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.

ABSTRACT:

Importance

The Inflation Reduction Act of 2022 authorizes Medicare to negotiate prices of top-selling drugs based on several factors, including therapeutic benefit compared with existing treatment options.

Objective

To determine the added therapeutic benefit of the 50 top-selling brand-name drugs in Medicare in 2020, as assessed by health technology assessment (HTA) organizations in Canada, France, and Germany.

Design, setting, and participants

In this cross-sectional study, publicly available therapeutic benefit ratings, US Food and Drug Administration documents, and the Medicare Part B and Part D prescription drug spending dashboards were used to determine the 50 top-selling single-source drugs used in Medicare in 2020 and to assess their added therapeutic benefit r

SUBMITTER: Egilman AC 

PROVIDER: S-EPMC10114018 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature